[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitral-regurgitation-mr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitral-regurgitation-mr":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,51,88,114,138,163,190,220],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100649922","precise-afmr-i-transcatheter-mitral-valve-edge-to-edge-repair-for-atrial-functional-mitral-regurgitation-in-patients-at-high-surgical-risk-100649922",false,"NCT07741253","PRECISE-AFMR I: Transcatheter Mitral Valve Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation in Patients at High Surgical Risk","PRECISE-AFMR I: A Prospective Randomized Controlled Trial of Transcatheter Mitral Valve Edge-to-Edge Repair in Patients With Atrial Functional Mitral Regurgitation at High Surgical Risk","PRECISE-AFMR I","Inclusion Criteria:\n\n* 1\\. Aged ≥18 years;\n\n  2\\. Presence of symptoms of heart failure, with New York Heart Association (NYHA) functional class II, III, or ambulatory class IV;\n\n  3\\. Confirmed by preliminary assessment of the study-site Heart Team and review by the Echocardiography Core Laboratory (ECL) to have at least moderate-to-severe atrial functional mitral regurgitation (AFMR), generally graded as 3+ or 4+;\n\n  4\\. At least one hospitalization for heart failure within the 12 months prior to enrollment and\u002For a plasma B-type natriuretic peptide (BNP) level ≥300 pg\u002FmL or N-terminal pro-B-type natriuretic peptide (NT-proBNP) level ≥1,500 pg\u002FmL;\n\n  5\\. As confirmed by a heart failure specialist at the study site, the subject has received maximally optimized guideline-directed medical therapy (GDMT) and other necessary standardized comprehensive treatment in accordance with current guidelines for at least 3 months. For subjects with concomitant atrial fibrillation, coronary artery disease, or other potentially correctable comorbidities, appropriate evaluation and guideline-recommended management must have been completed, or the subject must have been clearly determined to be unsuitable for further treatment;\n\n  6\\. Determined by the multidisciplinary Heart Team, in accordance with the process described in Section 4.7, to be at high surgical risk, to have a contraindication to surgery, or to be unsuitable for surgery, or determined after comprehensive assessment that surgical treatment is not the optimal current strategy;\n\n  7\\. During the screening period or within 90 days prior to randomization, mitral valve anatomy is assessed by echocardiography at the study site and confirmed by the ECL to be suitable for transcatheter edge-to-edge repair (TEER). Anatomical suitability must meet at least all of the following criteria:\n  * Mitral valve area \\>4.0 cm² and baseline mean transmitral pressure gradient \\\u003C4 mmHg;\n\n    * Adequate mobility or sufficient graspable leaflet tissue in the target grasping area, with a mobile\u002Fgraspable leaflet length ≥10 mm;\n\n      * Mitral annular anteroposterior diameter ≤40 mm;\n\n        * Left atrial volume index (LAVI) \\\u003C85 mL\u002Fm²;\n\n          ⑤ Leaflet-to-annulus index (LAI) \\>1.10;\n\n          8\\. The transseptal puncture route and femoral venous access are considered suitable for TEER by the investigator or Heart Team;\n\n          9\\. The subject or the subject's legally authorized representative voluntarily agrees to comply with the requirements of the study protocol, including the possibility of being randomized to the optimized GDMT group, and provides written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Presence of primary structural mitral valve disease that can independently account for the mitral regurgitation (MR), such as leaflet prolapse, flail leaflet, rheumatic valvular disease, leaflet perforation, or damage resulting from infective endocarditis;\n\n  2\\. Functional mitral regurgitation other than atrial functional mitral regurgitation (AFMR), including ventricular functional mitral regurgitation caused by left ventricular dilatation, regional wall-motion abnormalities, ischemic cardiomyopathy, dilated cardiomyopathy, or other conditions involving the myocardium, including restrictive cardiomyopathy, hypertrophic cardiomyopathy, and infiltrative cardiomyopathy such as amyloidosis, hemochromatosis, or sarcoidosis;\n\n  3\\. Presence of pericardial disease, such as constrictive pericarditis, that may be the predominant mechanism underlying heart failure or MR;\n\n  4\\. Prior surgical mitral valve intervention or transcatheter mitral valve intervention;\n\n  5\\. Concomitant moderate-to-severe or greater disease of another heart valve requiring surgical or transcatheter intervention;\n\n  6\\. An acute cerebrovascular event within the previous 30 days;\n\n  7\\. Cardiovascular or cerebrovascular surgery or interventional treatment within the previous 30 days, including coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), transcatheter aortic valve replacement (TAVR), or transcatheter carotid artery stenting;\n\n  8\\. Severe symptomatic carotid artery stenosis, defined as \\>70% stenosis on ultrasonography;\n\n  9\\. Hemodynamic instability requiring continuous intravenous drug infusion or mechanical circulatory support;\n\n  10\\. Pulmonary artery systolic pressure (PASP) \\>70 mmHg as estimated by echocardiography, or pulmonary vascular resistance (PVR) \\>3 Wood units as measured by right heart catheterization;\n\n  11\\. Symptoms, signs, or echocardiographic evidence of severe right ventricular dysfunction, such as tricuspid annular plane systolic excursion (TAPSE) \\\u003C15 mm or peak systolic tissue Doppler velocity (S') \\\u003C10 cm\u002Fs;\n\n  12\\. Chronic renal insufficiency requiring long-term hemodialysis;\n\n  13\\. Severe liver cirrhosis accompanied by esophageal varices;\n\n  14\\. Prior heart transplantation;\n\n  15\\. Severe chronic obstructive pulmonary disease (COPD) requiring continuous home oxygen therapy or long-term oral glucocorticoid therapy;\n\n  16\\. Severe hematologic disease;\n\n  17\\. A modified Rankin Scale score ≥4, indicating moderately severe or severe disability;\n\n  18\\. Mitral valve anatomical features that, as assessed by echocardiography at the study site and confirmed by the Echocardiography Core Laboratory (ECL), may prevent safe implantation, appropriate positioning, stable leaflet grasping, or adequate reduction of MR with the transcatheter edge-to-edge repair (TEER) device. Such features include, but are not limited to, insufficient leaflet mobility or insufficient graspable leaflet tissue in the target grasping area, significant calcification in the grasping area, a prominent leaflet cleft, leaflet perforation, severe leaflet thickening, fibrosis, retraction, or severely restricted leaflet mobility, insufficient primary or secondary chordal support, or any other anatomical feature that, in the judgment of the ECL, may result in technical failure of TEER, significant residual MR, or an increased risk of clinically significant mitral stenosis after the procedure;\n\n  19\\. An intracardiac mass, thrombus, or vegetation detected by echocardiography;\n\n  20\\. A contraindication to, or a high risk associated with, transesophageal echocardiography;\n\n  21\\. Inadequate echocardiographic image quality;\n\n  22\\. Known allergy or contraindication to any medication or device material required for the TEER procedure;\n\n  23\\. Pregnancy, breastfeeding, or intention to become pregnant within the following 12 months;\n\n  24\\. Anticipated need for emergency surgery or elective cardiac surgery for any reason within the following 12 months;\n\n  25\\. Life expectancy of \\\u003C12 months due to a noncardiac condition;\n\n  26\\. The subject is a member of a vulnerable population or has a condition that may impair their ability to provide written informed consent and\u002For comply with study procedures;\n\n  27\\. Current participation in another interventional drug or device trial that may interfere with the assessment of the primary endpoint of this study;\n\n  28\\. Any other condition that, in the judgment of the investigator, ECL, or EC, renders the subject unsuitable for participation in this study.","ALL","18 Years",{"count":20,"type":21},182,"ESTIMATED","INTERVENTIONAL",[24],"NA","Atrial functional mitral regurgitation (AFMR) develops when enlargement and remodeling of the left atrium and mitral annulus prevent the mitral valve leaflets from closing completely, allowing blood to leak backward through the valve. For patients with significant AFMR who remain symptomatic despite medical treatment and are at high risk for surgery, it is uncertain whether adding transcatheter mitral valve edge-to-edge repair (TEER), a catheter-based procedure that brings the mitral valve leaflets together, provides better outcomes than medical treatment alone.\n\nPRECISE-AFMR I is a prospective, multicenter, randomized study that will enroll 182 adults with moderate-to-severe or severe AFMR, high or prohibitive surgical risk, and mitral valve anatomy suitable for TEER. Participants will be assigned in a 1:1 ratio to receive TEER plus optimized guideline-directed medical therapy (GDMT) or optimized GDMT alone. All participants will receive standardized medical care and will be followed for 12 months.\n\nThe main effectiveness outcome is the occurrence of death from any cause or hospitalization for heart failure within 12 months. The main safety outcome is the occurrence of major device-related adverse events within 12 months. The study will also assess mitral regurgitation severity, symptoms, functional capacity, quality of life, heart failure events, and use of health care resources.",[27,28],"Atrial Functional","Mitral Regurgitation (MR)",[30,31,32,33,34,35,36,37],"Atrial functional mitral regurgitation","Transcatheter edge-to-edge repair","TEER","MitraClip","Guideline-directed medical therapy","High surgical risk","Secondary mitral regurgitation","Heart failure hospitalization","NOT_YET_RECRUITING","2026-07-29",{"date":41,"type":42},"2026-08-03","ACTUAL",{"date":44,"type":21},"2026-08",{"date":46,"type":21},"2027-12",{"name":48,"class":49},"China National Center for Cardiovascular Diseases","OTHER_GOV",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":50},"100608144","delineate-prospective-100608144","NCT07197736","DELINEATE-Prospective","Deep Learning for Echo Analysis, Tracking, and Evaluation Prospective Evaluation (DELINEATE-Prospective)","DELINEATE","Inclusion Criteria:\n\n* Attending cardiologist employed by Columbia University, ColumbiaDoctors, or NewYork Presbyterian Hospital who reads transthoracic echocardiograms in the Columbia echocardiography laboratory\n* Provided informed consent to take part in the questionnaires or pivotal study\n\nExclusion Criteria:\n\n* Physician in training (cardiology fellow or advanced imaging fellow)",{"count":60,"type":21},50,"OBSERVATIONAL","Heart disease is the leading cause of death in the United States, and echocardiography (or \"echo\") is the most common way doctors look at the heart. Echo is safe, painless, and can detect major heart problems, including weak heart pumping and valve disease.\n\nValve disease, especially aortic stenosis (narrowing) and mitral regurgitation (leakage), is common in older adults but often goes undiagnosed. While echo is the main tool for finding valve problems, it takes time, requires expert training, and results can vary between readers.\n\nRecent advances in artificial intelligence (AI), especially deep learning (DL), have shown promise in automatically analyzing heart images. However, past research hasn't fully tackled key echo techniques-like color Doppler and spectral Doppler-that are crucial for measuring how blood moves through heart valves. AI tools also face challenges in being used in everyday medical practice because of workflow issues, lack of real-world testing, and concerns about how the algorithms make decisions.\n\nAt Columbia University Irving Medical Center, researchers have built a large database of heart tests over the last six years and developed AI programs to analyze echocardiograms. The current study will test whether providing AI analysis to cardiologists in real time during echo reading can make the process faster and more consistent.",[64,28,65,66,67,68],"Valve Disease, Aortic","Aortic Stenosis","Valvular Heart Disease","Tricuspid Regurgitation (TR)","Aortic Regurgitation",[70,71,72,73,74,75,76],"artificial intelligence","deep learning","valvular heart disease","echocardiography","cardiovascular disease","mitral regurgitation","aortic stenosis","RECRUITING","2026-04-14",{"date":80,"type":42},"2026-04-16",{"date":82,"type":21},"2026-04-15",{"date":84,"type":21},"2028-10-01",{"name":86,"class":87},"Columbia University","OTHER",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":50},"100631480","safety-and-feasibility-study-of-the-mitrafix-transcatheter-mitral-valve-system-100631480","NCT07501234","Safety and Feasibility Study of the MitraFix® Transcatheter Mitral Valve System","A Prospective Clinical Study to Evaluate the Safety and Clinical Feasibility of the MitraFix® Transcatheter Mitral Valve System","MITRA-EFS","Inclusion Criteria:\n\n* Moderate to severe or severe (≥3+) mitral regurgitation.\n* Age ≥ 18 years.\n* Patients at high risk for traditional open-heart surgery, defined as: STS mortality risk for mitral valve replacement ≥ 8%; OR presence of 2 or more frailty indices; OR presence of 2 or more major organ dysfunctions that cannot be improved post-operatively; OR other comorbidities or factors making them unsuitable for surgery.\n* Anatomically suitable for transcatheter MitraFix® system implantation via a transfemoral-transseptal approach as assessed by the investigator; the transfemoral-transseptal access route meets the requirements of the delivery system.\n* Able to understand the study purpose, voluntarily participate, sign the informed consent form, and willing to accept relevant examinations and clinical follow-ups.\n\nExclusion Criteria:\n\n* Severe mitral stenosis.\n* Severe calcification of mitral leaflets and\u002For annulus; anatomical structures of the mitral valve apparatus (e.g., papillary muscles) unsuitable for device implantation.\n* High risk of left ventricular outflow tract obstruction (LVOTO) based on pre-operative CT\u002FTEE planning (estimated neo-LVOT \\\u003C 150 mm²), which cannot be avoided by procedural optimization.\n* Presence of previous implants in the mitral position (surgical bioprosthetic or mechanical valves, surgical annuloplasty rings, etc.).\n* Infective endocarditis or evidence of active infection.\n* Stroke or transient ischemic attack (TIA) within 90 days.\n* Severe untreated coronary artery disease or acute myocardial infarction within 90 days; or percutaneous coronary intervention (PCI)\u002Fcoronary stent implantation within 90 days.\n* Severe pulmonary hypertension (resting PASP \\> 70 mmHg, assessed as irreversible).\n* Severe right ventricular dysfunction: Tricuspid Annular Plane Systolic Excursion (TAPSE) \\\u003C 17 mm.\n* Concomitant tricuspid valve, aortic valve, or severe great vessel disease requiring surgical or interventional treatment.\n* Left ventricular ejection fraction (LVEF) \\\u003C 30%.\n* Extreme frailty preventing tolerance of the procedure, or in a state of shock requiring circulatory support.\n* Implantation of CRT, CRT-D, or implantable cardioverter-defibrillator (ICD) within 30 days.\n* Chronic dialysis or expected need for long-term dialysis; or severe renal impairment (e.g., eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²) unable to undergo perioperative dialysis.\n* Documented coagulopathy or severe hematological disorders (e.g., platelet count \\\u003C 50×10\\^9\u002FL, active bleeding), or history of heparin-induced thrombocytopenia (HIT).\n* Contraindications to anticoagulant\u002Fantiplatelet therapy that cannot be substituted or bridged.\n* Echocardiographic evidence of any intracardiac mass, or thrombus in the left ventricle or left atrium (including left atrial appendage).\n* Contraindications to transesophageal echocardiography (TEE).\n* Severe allergy to iodine contrast media, nitinol, bovine-derived materials, or other device materials that remains intolerable despite premedication.\n* Life expectancy \\\u003C 12 months.\n* Pregnant or breastfeeding women.\n* Unsuitable for the transfemoral-transseptal approach (e.g., femoral vein diameter, calcification, tortuosity, or atrial septum\u002Fleft atrial anatomy not meeting delivery system requirements).\n* Participation in another clinical study of an investigational device or drug within 3 months prior to screening that may interfere with this study.\n* Any other conditions deemed unsuitable for enrollment by the investigator.",{"count":97,"type":21},5,[24],"The goal of this early feasibility clinical trial is to test a new device called the MitraFix® Transcatheter Mitral Valve System. It aims to learn if the device is safe and if it can help adults who have a severe leaky heart valve (mitral regurgitation). This study is for people who are at high risk for traditional open-heart surgery.\n\nThe main questions it aims to answer are:\n\nIs the MitraFix system safe for participants? Can the device be successfully placed in the heart? Does the device help reduce the valve leak and improve daily life?\n\nParticipants will:\n\nReceive the MitraFix valve through a small tube inserted into a vein in the leg.\n\nVisit the clinic for heart tests, walking tests, and health checks for up to one year after the procedure.",[28],[102,103],"MitraFix","Transcatheter Mitral Valve Replacement","2026-03-26",{"date":106,"type":42},"2026-03-30",{"date":108,"type":21},"2026-03-23",{"date":110,"type":21},"2028-10-23",{"name":112,"class":113},"Mitrassist Lifesciences Limited Co., Ltd.","INDUSTRY",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":121,"targetDuration":123,"studyType":61,"phases":4,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100624768","mitral-valve-repair-with-the-chord-x-system-a-long-term-evaluation-100624768","NCT07413926","Mitral Valve Repair With the Chord-X System: A Long Term Evaluation","METRIX","Inclusion Criteria:\n\n* Patient provided written Informed Consent\n* Patient underwent mitral valve procedure (defined as mitral valve surgical intervention via endoscopic, mini thoracotomy, or full sternotomy approach, including mitral annuloplasty with a ring, resection of mitral valve leaflets, and replacement of mitral chordae tendineae) using the Chord-X System as clinically indicated (i.e. not off-label) by Principal Investigator at research site\n* Patient's Chord-X System implant occurred no earlier than January 1, 2022\n* Patient is able and willing to participate in follow-up visits for the duration of the study (i.e. through 10 years post-op)\n\nExclusion Criteria:\n\n* Patient was implanted with the Chord-X System off-label\n* Patient was implanted with the Chord-X System prior to January 1, 2022\n* Patient has had previous mitral valve surgery\n* Patient underwent a multi valve repair procedure\n* Patient with an ejection fraction ≤ 50% at baseline\n* Patient underwent concomitant surgical procedures (except for maze procedure, PFO or LAA closure) at time of mitral repair procedure\n* Patient whose mitral valve procedure was performed as part of an emergency surgery (defined as a time period from diagnosis to surgery of ≤ 48 hours)\n* Patient with persistent or permanent atrial fibrillation\n* Patient with active or a history of endocarditis\n* Patient with congenital heart disease",{"count":122,"type":21},110,"10 Years","The goal of this clinical trial is to strengthen the evidence available for the Chord-X System by collecting follow-up data from patients who underwent Chord-X implant and to evaluate the long-term safety and performance data (out to 10 years). Collecting patient health information over time can help to supplement and improve the care of patients in the future.\n\nParticipants will:\n\nAgree to the collection of their past medical history, and the details of their mitral repair surgery with the Chord-X system, including results of the follow-up examinations after implantation Visit the clinic for the routinely scheduled follow-up examination appointments",[28],[75,127],"Chord-X","2026-02-18",{"date":130,"type":42},"2026-02-20",{"date":132,"type":21},"2026-06",{"date":134,"type":21},"2034-06",{"name":136,"class":113},"Artivion Inc.",4,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":145,"targetDuration":147,"studyType":61,"phases":4,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":4},"100612000","research-on-the-development-and-application-of-a-preoperative-assessment-model-for-transcatheter-mitral-valve-edge-to-edge-repair-based-on-visual-foundation-models-100612000","NCT07247890","Research on the Development and Application of a Preoperative Assessment Model for Transcatheter Mitral Valve Edge-to-Edge Repair Based on Visual Foundation Models","Inclusion Criteria:\n\n1. Age: 18-90 years\n2. Patients with moderate to severe or severe mitral regurgitation as indicated by echocardiography\n\nExclusion Criteria:\n\n1. Moderate or severe aortic stenosis or aortic regurgitation, or following aortic valve replacement\n2. Patients with congenital heart disease\n3. Poor image quality: Insufficient cross-sectional coverage or inability to perform effective mitral valve marking","90 Years",{"count":146,"type":21},800,"2 Days","Mitral regurgitation (MR) is the most prevalent valvular heart disease in China. Transcatheter edge-to-edge repair (TEER) is currently the preferred treatment for patients with severe MR who face high surgical risks. However, existing preoperative assessment methods for TEER suffer from numerous limitations, including complex measurement parameters, high technical demands, and significant subjectivity. Vision Mamba, a cutting-edge technology in the visual domain, overcomes the limitations of common computational units in convolutional neural networks and Transformers through bidirectional state space models and positional encoding, demonstrating exceptional performance in visual tasks. To date, no studies have applied Vision Mamba to ultrasound videos for constructing TEER preoperative assessment models. Our team previously established a Transformer-based evaluation model using a small, single-center cohort. This study innovatively introduces a Vision Mamba-based visual foundation model. By integrating multi-faceted, multi-modal ultrasound videos from multiple centers, we develop a one-stop preoperative TEER assessment model for MR patients \\[slice identification → video analysis → multi-modal information fusion → preoperative assessment recommendation (suitable\u002Fchallenging\u002Funsuitable)\\]. This model will optimize surgical patient identification and accurately screen patients with contraindications. Furthermore, the one-stop model is fast and objective, significantly improving clinical efficiency. It holds promise for deployment at primary care levels to optimize healthcare resource allocation.",[28],[151,152,153,154],"Mitral regurgitation (MR)","Transcatheter Mitral Valve Edge-to-Edge Repair","Vision Mamba","Visual Foundation Model","2025-11-18",{"date":157,"type":42},"2025-11-25",{"date":159,"type":21},"2025-12",{"date":46,"type":21},{"name":162,"class":49},"Beijing Hospital",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":50},"100583481","mitral-regurgitation-risk-assessment-and-clinical-modelling-100583481","NCT06876883","MItral Regurgitation Risk Assessment and CLinical modElling","MItral Regurgitation Risk Assessment and CLinical modElling (MIRACLE Study)","MIRACLE","Inclusion Criteria:\n\n* Patients diagnosed with ≥ moderate mitral regurgitation during hospitalization.\n* Aged over 18 yrs.\n\nExclusion Criteria:\n\n* Patients unable to provide written consent.",{"count":172,"type":21},2000,"Mitral regurgitation (MR) is a common valvular heart disease worldwide, and untreated severe MR is associated with an elevated risk of heart failure and mortality. According to causes, MR could be divided into primary or secondary MR. The risk factors of mortality or heart failure hospitalization in different types of MR patients are under intensive investigation.\n\nMItral Regurgitation risk Assessment and CLinical modElling (MIRACLE) study is a prospective cohort study including adult patients diagnosed with ≥ moderate MR during hospitalization. Comprehensive echocardiographic examination was conducted at baseline evaluating valvular heart disease severity, atrial and ventricular systolic\u002Fdiastolic function, pulmonary artery systolic pressure (PASP), etc. We aim to evaluate the prognostic risk factors of patients with MR and construct a prognostic clinical model to guide clinical decision-making.",[175,28],"Mitral Insufficiency",[75,177,178,179,180],"all-cause mortality","clinical modelling","cardiovascular mortality","heart failure hospitalization","2025-08-28",{"date":183,"type":42},"2025-09-05",{"date":185,"type":42},"2016-06-15",{"date":187,"type":21},"2030-06-15",{"name":189,"class":87},"Sun Yat-sen University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100598085","quantification-of-mitral-regurgitation-using-4d-mri-flow--comparison-with-2d-mri-flow-and-echocardiography-using-the-evolution-of-left-ventricular-remodeling-as-a-reference-100598085","NCT07066904","Quantification of Mitral Regurgitation Using 4D MRI Flow : Comparison With 2D MRI Flow and Echocardiography Using the Evolution of Left Ventricular Remodeling as a Reference","FLAME","Inclusion Criteria: Subjects\n\n* from 18 to 85 years old\n* having signed a consent form to participate in the study\n* suffering from mild, moderate or severe mitral regurgitation based on an ultrasound graduation\n* able to undergo echocardiography and IRM within 7 days after recruitment and then at 6 months\n\nExclusion Criteria: Subjects\n\n* suffering from aortic regurgitation or stenosis or mitral stenosis associated with more than moderate MR, intracardiac shunting or hypertrophic cardiomyopathy\n* suffering from secondary MR\n* having a contraindication to gadolinium-based contrast agent\n* having a pacemaker, defibrillator or any other contraindication to MRI\n* suffering from renal disease with an eGFR CKD-EPI \\\u003C 30 ml\u002Fmin\n* pregnant or breastfeeding\n* under legal protection\n\nEnrolled subjects:\n\n* with an incomplete or suboptimal ultrasound or MRI examination\n* who have not attended to the 6-month follow-up visit\n* with an intercurrent medical event\n\nwill be excluded.","85 Years",{"count":199,"type":21},160,[24],"The goal of this study is to evaluate whether 4D MRI provides a better assessment of mitral regurgitation quantification and associated ventricular remodeling than standard imaging techniques: echocardiography and 2D MRI, in patients suffuring from mitral regurgitation. 4D MRI demonstrated its superiority to 2D MRI in some other valve diseases but remains not widely used, due to a lack of evidence. The main question our study aims to answer is:\n\n• Is mitral regurgitant volume measured on 4D MRI more strongly related to remodeling progression (after correction of regurgitation or not) than regurgitant volume measured on 2D MRI and echocardiography?\n\nParticipants will undergo 4D MRI, 2D MRI and echocardiography twice at six-month intervals.",[28],[204,205,206,207,208,209],"Mitral regurgitation","4D MRI","4D-flow MRI","cardiovascular magnetic resonance","Ultrafast ultrasound imaging","ultrafast echocardiography","2025-07-04",{"date":212,"type":42},"2025-07-15",{"date":214,"type":21},"2025-10-01",{"date":216,"type":21},"2028-04-30",{"name":218,"class":87},"Assistance Publique - Hôpitaux de Paris",3,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":50},"100596461","the-prospective-segeberg-registry-for-mitral-transcatheter-edge-to-edge-repair-100596461","NCT07045753","The Prospective Segeberg Registry for Mitral Transcatheter Edge-to-Edge Repair","A Prospective Follow-up Assessment in Bad Segeberg With Patients With Severe Mitral Regurgitation Undergoing Mitral Edge-to-edge Repair (M-TEER).","SK M-CLIP","Inclusion Criteria:\n\n* Patients with severe MR undergoing M-TEER\n\nExclusion Criteria:\n\n* None","100 Years",{"count":172,"type":21},"A Prospective Follow-up Assessment in Bad Segeberg for Patients with severe MR undergoing M-TEER",[28],[233,234],"M TEER","Mitral Clip","2025-06-22",{"date":237,"type":42},"2025-07-01",{"date":239,"type":42},"2011-01-01",{"date":241,"type":21},"2032-12-31",{"name":243,"class":87},"Segeberger Kliniken GmbH"]